Develop
Our idea is to integrate immunohistochemistry as early as possible in the hybridoma screening procedure and thereby expand the classical ELISA screen by histopathological expertise at an early stage of FFPE antibody development.
01 / Antibody intelligence, made actionable
Validation
starts in the tissue.
Monoclonal research antibodies for researchers, pathologists and biomarker teams who need evidence they can inspect.
CD8 × CD112R multiplexHuman tonsil · Clones TC8 + R12 · Fluorescence IHC
Developed with histopathologyONCOdianova is an antibody manufacturing network linking antibody development to histopathological validation.
Tissue-profiledOur antibodies have been tested on many different tumor and normal tissues.
Validated by pathologistsOur clones have been validated by pathologists from routine diagnostic laboratories.
Published evidenceClone-specific peer-reviewed use, cited with DOI where available.
Multiplex IHCDocumented in multiplex settings for selected clones.
For Research Use Only. Not for use in diagnostic procedures.
02 Scientific finder
Find the right signal.
Seven monoclonal clones for tissue-based immuno-oncology research — searchable by target, clone and application.
7 clones · RUO
TIGITClone TG1 · DIA-TG1-MClone TG1 allows the identification of TIGIT positive T-cells in standard FFPE human tumors. TG1 is a valuable tool for clinical research of the tumor microenvironment.Clone-specifically published mouse monoclonal anti-TIGIT antibody for human FFPE, brightfield and fluorescence multiplex IHC. RRID AB_3750391.Product page 
TIGITClone TG2 · DIA-TG2-MSeparate anti-TIGIT clone for IHC on human FFPE tissue.Product page 
CD112R / PVRIGClone R12 · DIA-R12Clone R12 is documented for brightfield IHC and fluorescence multiplex IHC on human FFPE tissue.Anti-CD112R/PVRIG antibody used in a peer-reviewed multiplex immunofluorescence study (Yang et al., Modern Pathology 2023).Product page 
FOXP3Clone FX3 · DIA-FX3Clone FX3 detects FOXP3 positive TILs in FFPE human tumors.Nuclear FOXP3 detection in human FFPE tissue; used in a peer-reviewed automated multiplex IF study (Picard et al., Acta Neuropathologica 2023).Product page 
CD8Clone TC8 · DIA-TC8Clone TC8 detects tumor infiltrating lymphocytes (TILs).Anti-CD8 antibody with five peer-reviewed clone-specific publications on large human tumor cohorts.Product page 
CD73Clone KK3 · DIA-KK3Clone KK3, validated for CD73 detection in FFPE tissue.Mouse monoclonal anti-CD73 (NT5E) antibody for IHC on routine human FFPE tissue; membranous staining pattern, tonsil as positive control; ten original ONCOdianova tissue figures.Product page 
Mutant CALR (calreticulin)Clone CAL2® · dedicated siteCAL2® — mutation-specific antibody for mutant CALR. Dedicated scientific information, methodology, evidence and ordering information are available at cal2antibody.com. For Research Use Only. Not for use in diagnostic procedures.Explore CAL2® No marker matches this search.
03 Antibody highlights
What these clones made possible.
The following antibody highlights from ONCOdianova are documented in peer-reviewed tissue-based research:
TIGIT
Clone TG1 · DIA-TG1-M
TIGIT is one of the most important checkpoint markers for the development of new immunotherapies against cancer. The TG1 evidence base comprises twelve peer-reviewed IHC references plus one separately presented peer-reviewed Imaging Mass Cytometry publication.
New application evidenceTG1 in highly multiplexed Imaging Mass Cytometry
Product pagePVRIG / CD112R
Clone R12 · DIA-R12
PVRIG / CD112R plays an important role in the development of effective combination therapies with PD1 and TIGIT. Clone R12 was used in a peer-reviewed four-marker fluorescence multiplex IHC study of a cohort of 523 colorectal cancers.
Product page
Explore the new anti-TIGIT clone TG2 now with higher staining intensity.
Explore TG2Our strong feedback from laboratories applying the new ONCOdianova antibodies against CD112R, TIGIT and CALRmut shows that they are perceived as innovative tools for immunohistochemistry, because they allow new approaches for tissue based studies of important biomarkers.
04 How we work
Four pillars. One standard.
ONCOdianova is an antibody manufacturing network focused on research antibodies for human FFPE IHC and fluorescence multiplex applications. In multiplex IHC, several markers are examined in parallel under coordinated staining conditions. ONCOdianova combines hybridoma development with histopathological evaluation in human tissue research.
For Research Use Only. Not for use in diagnostic procedures.
Validate
We use our strong network for histopathological validation of new targets in human tissues. This expands our expertise to develop new test systems for novel targets. For cancer immunology targets we put a focus on tumor infiltrating lymphocytes.
Improve
Multiplex Assay technology develops fast and depends on the availability of reliable antibody reagents. Our vision is to provide documented cancer-immunology research antibodies for combined use in tissue-based studies.
Partner
Our objective is to potentially develop multiple clones for the same target by approaching one target at diverse immunogenic sites. We are able to reference mapped epitopes and open for beta testing opportunities with pharmaceutical partners.
05 Validation framework
A method you can
inspect.
Every product page documents peer-reviewed clone-specific evidence, congress abstracts and technical specifications, with references, catalog numbers and RRIDs where assigned.
Request a data packageEvidence layer 01
Clone selection
Context-led clone evaluation with immunohistochemistry integrated early in development.
Evidence layer 02
Pattern profiling
Pattern assessment across human normal and tumor tissues with defined positive controls.
Evidence layer 03
Published evidence
Clone-specific use documented in peer-reviewed studies where available — each cited with DOI on the product page.
Designed for the questionFrom marker
From marker
to meaning.
Products are organised around the questions research teams actually ask: immune phenotype, checkpoint axes, spatial arrangement and tumour context.
- Immuno-oncology markers
- Multiplex IHC panels
- FFPE tissue research
CD8 × CD112R multiplex · Human tonsil · Clones TC8 + R12
06 Ordering & next steps
Clear pathways for
every next step.
Orders are handled through BIOZOL Diagnostica Vertrieb GmbH. Every route maps a specialist question to a product, a document or a conversation.